CLSN News and Press, Celsion Corporation From 04/06/22

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Cor...

LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shar...

LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during...

Celsion Corporation (CLSN) Q4 2021 Earnings Conference Call March 31, 2022 11:00 A.M. ET Company Participants Monique Kosse - Managing Director, LifeSci Advisors Michael Tardugno - Chairman, President and Chief Executive Officer Jeffrey Church - Senior Vice President, Chief Financial Officer ...

Celsion press release (NASDAQ:CLSN): FY GAAP EPS of -$3.83 beats by $0.22. Revenue of $0.5M in-line (flat Y/Y). For further details see: Celsion GAAP EPS of -$3.83 beats by $0.22, revenue of $0.5M in-line

Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development ...

ACTG, AFMD, OTCPK:BRPHF, OTCQX:CBWTF, CLSN, GOED, LTRY, NNDM, NNOX, PDSB, PLX, PTR, TRVN, WBA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ...

Celsion (CLSN) received $1.4M in net cash proceeds from the sale of ~$1.5M of its unused New Jersey net operating losses. Strengthening its balance sheet, this non-dilutive funding adds to the $55M+ in gross proceeds from equity offerings completed in 2021. Over ...

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (...